Lourdes Anta

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Tissue Engineering

Hyaluronic Acid

Top Venues

British journal of clinical pharmacology

Neuropsychiatric disease and treatment

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Christian Laveille, Eric Snoeck, Lourdes Ochoa Díaz de Monasterioguren, Javier Martínez-González, Jordi Llaudó, Lourdes Anta, Ibon Gutierro
Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®. British journal of clinical pharmacology (2024)
Christian Laveille, Eric Snoeck, Lourdes Ochoa Díaz de Monasterioguren, Javier Martínez-González, Jordi Llaudó, Lourdes Anta, Ibon Gutierro
Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®. British journal of clinical pharmacology 90 (9) (2024)
Christian Laveille, Eric Snoeck, Lourdes Ochoa Díaz de Monasterioguren, Javier Martínez-González, Jordi Llaudó, Lourdes Anta, Ibon Gutierro
Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®. British journal of clinical pharmacology 90 (9) (2024)
Robert Litman, Dieter Naber, Lourdes Anta, Javier Martínez, Yuriy Filts, Christoph U Correll
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric disease and treatment 19 (2023)
Robert Litman, Dieter Naber, Lourdes Anta, Javier Martínez, Yuriy Filts, Christoph U Correll
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric disease and treatment 19 (2023)
David P Walling, Howard A Hassman, Lourdes Anta, Lourdes Ochoa, Ignacio Ayani, Javier Martínez, Ibon Gutierro
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. Drug design, development and therapy 15 (2021)
Lourdes Anta, Elena Mata, Lourdes Ochoa Díaz de Monasterioguren
Newer Formulations of Risperidone: Remarks About Risperidone ISM®. CNS drugs 34 (10) (2021)